190.28
price down icon0.29%   -0.55
pre-market  Vorhandelsmarkt:  190.06   -0.22   -0.12%
loading
Schlusskurs vom Vortag:
$190.83
Offen:
$191.4
24-Stunden-Volumen:
3.78M
Relative Volume:
0.59
Marktkapitalisierung:
$336.11B
Einnahmen:
$57.37B
Nettoeinkommen (Verlust:
$4.20B
KGV:
80.97
EPS:
2.35
Netto-Cashflow:
$15.39B
1W Leistung:
+0.54%
1M Leistung:
+2.64%
6M Leistung:
+11.73%
1J Leistung:
+4.45%
1-Tages-Spanne:
Value
$188.53
$191.40
1-Wochen-Bereich:
Value
$184.63
$192.24
52-Wochen-Spanne:
Value
$163.81
$218.66

Abbvie Inc Stock (ABBV) Company Profile

Name
Firmenname
Abbvie Inc
Name
Telefon
(847) 932-7900
Name
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Mitarbeiter
55,000
Name
Twitter
@abbvie
Name
Nächster Verdiensttermin
2025-04-25
Name
Neueste SEC-Einreichungen
Name
ABBV's Discussions on Twitter

Vergleichen Sie ABBV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.28 337.08B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
LLY
Lilly Eli Co
812.69 723.06B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
168.30 407.97B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
117.70 227.39B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
71.70 314.28B 43.59B 15.04B 10.74B 3.3766

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-14 Herabstufung Citigroup Buy → Neutral
2025-04-22 Eingeleitet Cantor Fitzgerald Overweight
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-12-05 Herabstufung Daiwa Securities Outperform → Neutral
2024-11-22 Hochstufung Leerink Partners Market Perform → Outperform
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-11-04 Hochstufung Argus Hold → Buy
2024-10-17 Eingeleitet Bernstein Mkt Perform
2024-06-05 Hochstufung HSBC Securities Hold → Buy
2024-05-17 Eingeleitet Cantor Fitzgerald Overweight
2024-01-29 Hochstufung William Blair Mkt Perform → Outperform
2023-12-18 Herabstufung HSBC Securities Buy → Hold
2023-12-11 Hochstufung Goldman Neutral → Buy
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-10-30 Hochstufung Barclays Equal Weight → Overweight
2023-10-20 Fortgesetzt UBS Neutral
2023-09-29 Eingeleitet Raymond James Outperform
2023-07-25 Eingeleitet William Blair Mkt Perform
2023-07-14 Eingeleitet HSBC Securities Buy
2023-04-05 Herabstufung Argus Buy → Hold
2023-03-01 Eingeleitet Guggenheim Buy
2023-02-22 Herabstufung Wolfe Research Outperform → Peer Perform
2023-02-10 Hochstufung SVB Securities Underperform → Market Perform
2022-11-18 Eingeleitet Credit Suisse Outperform
2022-11-08 Herabstufung Societe Generale Buy → Hold
2022-08-01 Herabstufung Atlantic Equities Overweight → Neutral
2022-05-23 Eingeleitet SVB Leerink Underperform
2022-05-06 Herabstufung Daiwa Securities Outperform → Neutral
2022-04-06 Fortgesetzt Morgan Stanley Overweight
2022-02-28 Herabstufung UBS Buy → Neutral
2022-02-03 Bestätigt BMO Capital Markets Outperform
2022-02-03 Bestätigt Barclays Equal Weight
2022-02-03 Bestätigt BofA Securities Neutral
2022-02-03 Bestätigt Goldman Neutral
2022-01-13 Eingeleitet Redburn Buy
2022-01-12 Bestätigt BMO Capital Markets Outperform
2021-12-09 Fortgesetzt Wells Fargo Overweight
2021-11-23 Hochstufung Societe Generale Hold → Buy
2021-07-27 Fortgesetzt Truist Buy
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2020-11-10 Fortgesetzt Bernstein Outperform
2020-09-29 Eingeleitet Berenberg Hold
2020-06-23 Hochstufung Atlantic Equities Neutral → Overweight
2020-06-09 Hochstufung Wolfe Research Peer Perform → Outperform
2020-06-02 Hochstufung Argus Hold → Buy
2020-05-18 Fortgesetzt BofA/Merrill Neutral
2020-05-12 Hochstufung JP Morgan Neutral → Overweight
2020-05-11 Fortgesetzt Morgan Stanley Overweight
2020-04-20 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2020-03-23 Herabstufung Societe Generale Buy → Hold
2020-02-27 Eingeleitet Barclays Equal Weight
2020-02-06 Eingeleitet Mizuho Buy
2020-01-07 Eingeleitet RBC Capital Mkts Sector Perform
2019-12-26 Bestätigt Cowen Outperform
2019-09-26 Hochstufung Citigroup Neutral → Buy
2019-08-20 Hochstufung Piper Jaffray Neutral → Overweight
2019-06-27 Hochstufung Wolfe Research Underperform → Peer Perform
2019-06-26 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-05-28 Eingeleitet Goldman Neutral
2019-04-29 Hochstufung BMO Capital Markets Underperform → Market Perform
Alle ansehen

Abbvie Inc Aktie (ABBV) Neueste Nachrichten

pulisher
02:31 AM

Why AbbVie (ABBV) Is a High-Conviction Buy Despite Mixed Analyst Sentiment - AInvest

02:31 AM
pulisher
02:26 AM

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT - Insider Monkey

02:26 AM
pulisher
02:02 AM

AbbVie (ABBV) Positioned for Growth With Strong Skyrizi, Rinvoq Sales, Says JPMorgan - Insider Monkey

02:02 AM
pulisher
Jul 27, 2025

Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. - The Motley Fool

Jul 27, 2025
pulisher
Jul 27, 2025

What catalysts could drive AbbVie Inc. stock higher in 2025Consistent high-yield stocks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

AbbVie’s Phase 3 Study on Telisotuzumab Vedotin: A Potential Game-Changer in NSCLC Treatment - The Globe and Mail

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about AbbVie Inc. stockGame-changing returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Is AbbVie Inc. a good long term investmentExplosive portfolio gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

AbbVie’s Phase 3 Study on Upadacitinib for SLE: A Potential Game Changer? - The Globe and Mail

Jul 25, 2025
pulisher
Jul 25, 2025

AbbVie’s Latest Clinical Study on Glaucoma Gel Stent: Market Implications - The Globe and Mail

Jul 25, 2025
pulisher
Jul 24, 2025

What drives AbbVie Inc. stock priceExceptional portfolio growth - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

MHRA approves AbbVie’s Elahere - The Pharma Letter

Jul 24, 2025
pulisher
Jul 24, 2025

AbbVie’s Pediatric Atopic Dermatitis Study: A Potential Game-Changer? - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

AbbVie’s Long-term Study on Bimatoprost SR: Market Implications and Study Insights - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

September 5th Options Now Available For AbbVie (ABBV) - Nasdaq

Jul 24, 2025
pulisher
Jul 24, 2025

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Jul 24, 2025
pulisher
Jul 24, 2025

The 3 Things That Matter for AbbVie Now - Yahoo Finance

Jul 24, 2025
pulisher
Jul 24, 2025

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Staar Surgical (STAA) and Universal Health (UHS) - The Globe and Mail

Jul 24, 2025
pulisher
Jul 24, 2025

Endometriosis Drugs Market Growing at Robust Expansion of the Decade: AbbVie, Pfizer, Astellas Pharma - openPR.com

Jul 24, 2025
pulisher
Jul 23, 2025

Final Trades: Abbvie, Uber, Western Union and Live Nation - CNBC

Jul 23, 2025
pulisher
Jul 23, 2025

Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports - Yahoo Finance

Jul 23, 2025
pulisher
Jul 22, 2025

AbbVie (ABBV) Outperforms Broader Market: What You Need to Know - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

AbbVie Inc. Stock Analysis and ForecastBreakthrough profits - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Lip Fillers Market Is Booming So Rapidly 2025-2032Allergan (AbbVie Inc.), Galderma S.A., Merz Pharma - openPR.com

Jul 22, 2025
pulisher
Jul 22, 2025

Why AbbVie (ABBV) is a Strong Buy for Diversified Portfolios in a Volatile Market - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

4 Reasons To Buy AbbVie (NYSE:ABBV) - Seeking Alpha

Jul 22, 2025
pulisher
Jul 22, 2025

How Will AbbVie's Neuroscience Franchise Perform In Q2 Earnings? - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

IGI, Abbvie team up to advance myeloma treatment ISB 2001 - Rare Cancer News

Jul 22, 2025
pulisher
Jul 22, 2025

BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project - AbbVie News Center

Jul 22, 2025
pulisher
Jul 22, 2025

BOTOX Invests $400,000 in Women Entrepreneurs Through Elite 12-Week Business Accelerator Program - Stock Titan

Jul 22, 2025
pulisher
Jul 21, 2025

Lobbying Update: $1,160,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

AbbVie's Allergan wins $56 million in Botox patent fight - Crain's Chicago Business

Jul 21, 2025
pulisher
Jul 21, 2025

AbbVie unit wins $56 mln in US patent trial against Botox rival - Reuters

Jul 21, 2025
pulisher
Jul 21, 2025

AbbVie Unit Wins $56 Million from Revance Over Botox Patents (1) - Bloomberg Law News

Jul 21, 2025
pulisher
Jul 21, 2025

Stacey McCullough: I’m Thrilled to Join AbbVie Oncology Working in Market Access - Oncodaily

Jul 21, 2025
pulisher
Jul 21, 2025

Non-Small Cell Lung Cancer Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca - Barchart.com

Jul 21, 2025
pulisher
Jul 21, 2025

AbbVie’s Promising Phase 2 Study on ADPKD Treatment: What Investors Need to Know - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

AbbVie's Q1 2025 Earnings Surge 6.5% Year-Over-Year - AInvest

Jul 21, 2025
pulisher
Jul 20, 2025

AbbVie Stock (ABBV) Opinions on Recent Price Surge and Sales Growth - Quiver Quantitative

Jul 20, 2025
pulisher
Jul 20, 2025

Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT - MSN

Jul 20, 2025
pulisher
Jul 19, 2025

AbbVie’s Phase 3 Study on Atogepant: A Potential Game-Changer for Pediatric Migraine Prevention - TipRanks

Jul 19, 2025

Finanzdaten der Abbvie Inc-Aktie (ABBV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general JNJ
$168.30
price down icon 0.74%
drug_manufacturers_general NVS
$117.70
price up icon 0.20%
drug_manufacturers_general NVO
$71.70
price up icon 1.37%
drug_manufacturers_general MRK
$84.71
price up icon 0.71%
$306.58
price down icon 0.64%
Kapitalisierung:     |  Volumen (24h):